ESMO - Eur. Oncology· @myESMO · X·· 16 小时前评分70
正文 · 原文
The PD-1/VEGF bispecific antibody ivonescimab plus chemotherapy significantly improved overall survival in #BiliaryTractCancer in the phase III HARMONi-GI1 #ClinicalTrial presented in a Presidential Symposium at #ESMO26.
Read more:
🔗 https://ow.ly/YtKV50ZZGRl
#InsightsbyESMO
264 浏览 · 2 赞 · 0 转发 · 0 回复
来源：ESMO - Eur. Oncology · x.com